Trial Profile
A Multicenter, Open-Label Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Lacosamide (LCM) Oral Solution (Syrup) As Adjunctive Therapy In Children With Partial-Onset Seizures.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Lacosamide (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Sponsors UCB
- 14 Nov 2018 Population Pharmacokinetic results from SP0847 and SP1047 trials (n=79) published in the Journal of Clinical Pharmacology
- 05 Dec 2017 Interim pooled analysis results (cut-off date: 01 Nov 2016) from three open-label trials (NCT00938431,NCT00938912 and NCT01964560) presented at the 71st Annual Meeting of the American Epilepsy Society
- 14 Dec 2015 Study design changed from Randomized to non- randomized as reported by ClinicalTrials.gov.